Advanced Materials Technology (AMT), a US manufacturer and developer of columns for HPLC (High Performance Liquid Chromatography), and the Berlin-based Capsulution NanoScience AG signed in June a license contract for the use of the LBL® Technology that was originally developed for the manufacture of nano- and microcapsules by the Max Planck Society, Germany’s largest research foundation, and for which Capsulution owns the worldwide marketing rights. With this agreement, AMT is given access to the technology especially for the development and manufacture of HPLC columns containing a new generation of column packing materials.
“With this license, we are able to broaden our portfolio of key technologies so as to position ourselves as an innovative developer of hyper-fast and robust HPLC columns,” explains Dr. Joseph DeStefano, President of AMT. “New product developments based on the LBL® Technology should be ready for the market quickly. One promising area is the separation of macromolecules of biological interest such as proteins and DNA fragments where speed of analysis and selective separations are of high value.” adds DeStefano.
For Capsulution, this licensing is an important marketing success, providing additional resources which will be used for the future development of improved pharmaceutical products, thus underpinning their own company focus. One side-effect of this agreement has been greatly welcomed, especially in the company areas of research and development. “The use of our technology in the area of chromatographic applications is in line with our Inventors” explains Dr. Andreas Voigt, CSO of Capsulution. “After all, AMT researches in particular for those scientists requiring a more efficient and effective chromatographic separation. The planned innovative filling materials, which have functionalized layers based on our LBL® Technology should enable specific separation with the smallest samples at high speeds and will hopefully benefit us in our development of improved pharmaceutical products.”
“With this license, we are able to broaden our portfolio of key technologies so as to position ourselves as an innovative developer of hyper-fast and robust HPLC columns,” explains Dr. Joseph DeStefano, President of AMT. “New product developments based on the LBL® Technology should be ready for the market quickly. One promising area is the separation of macromolecules of biological interest such as proteins and DNA fragments where speed of analysis and selective separations are of high value.” adds DeStefano.
For Capsulution, this licensing is an important marketing success, providing additional resources which will be used for the future development of improved pharmaceutical products, thus underpinning their own company focus. One side-effect of this agreement has been greatly welcomed, especially in the company areas of research and development. “The use of our technology in the area of chromatographic applications is in line with our Inventors” explains Dr. Andreas Voigt, CSO of Capsulution. “After all, AMT researches in particular for those scientists requiring a more efficient and effective chromatographic separation. The planned innovative filling materials, which have functionalized layers based on our LBL® Technology should enable specific separation with the smallest samples at high speeds and will hopefully benefit us in our development of improved pharmaceutical products.”
